Insider Selling: Natera, Inc. (NASDAQ:NTRA) CFO Sells 946 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $171.98, for a total value of $162,693.08. Following the completion of the transaction, the chief financial officer now directly owns 109,474 shares in the company, valued at approximately $18,827,338.52. This represents a 0.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total value of $146,343.98.

Natera Trading Down 2.5 %

Shares of NASDAQ NTRA traded down $4.21 during trading on Friday, hitting $167.61. 909,104 shares of the company traded hands, compared to its average volume of 1,393,352. The company has a 50-day moving average price of $166.20 and a 200-day moving average price of $136.07. The firm has a market capitalization of $22.13 billion, a P/E ratio of -95.23 and a beta of 1.65. Natera, Inc. has a 1 year low of $62.96 and a 1 year high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% on a year-over-year basis. During the same period last year, the business posted ($0.95) EPS. On average, equities analysts predict that Natera, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares in the last quarter. Quarry LP increased its position in shares of Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after acquiring an additional 190 shares during the last quarter. Versant Capital Management Inc lifted its stake in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares in the last quarter. Covestor Ltd boosted its holdings in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares in the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms recently commented on NTRA. Morgan Stanley raised their price target on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Craig Hallum raised their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, TD Cowen upped their target price on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $162.94.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.